Product Description
IMMU-130 is composed of a drug attached to an antibody. The drug is the active ingredient in irinotecan which is a common chemotherapy drug used for colorectal cancer. For Metastatic Colorectal Cancer (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01915472)
Mechanisms of Action: CEACAM5 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Breast Cancer|Colorectal Cancer|Gastrointestinal Cancer|Intestinal Diseases|Liver Cancer|Digestive System Cancer|Pancreatic Cancer|Mouth Cancer
Phase 1: Colorectal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IM-T-hMN14-04 | P2 |
Completed |
Breast Cancer|Colorectal Cancer |
None |
|
| IM-T-hMN14-06 | P1 |
Terminated |
Colorectal Cancer |
None |
|
| IM-T-hMN14-02 | P2 |
Completed |
Colorectal Cancer |
None |
|
| CCaLM | P2 |
Not yet recruiting |
Gastrointestinal Cancer|Intestinal Diseases|Liver Cancer|Digestive System Cancer|Mouth Cancer|Colorectal Cancer |
None |